275 related articles for article (PubMed ID: 28932638)
1. The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.
Pazina T; James AM; MacFarlane AW; Bezman NA; Henning KA; Bee C; Graziano RF; Robbins MD; Cohen AD; Campbell KS
Oncoimmunology; 2017; 6(9):e1339853. PubMed ID: 28932638
[TBL] [Abstract][Full Text] [Related]
2. Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.
Pazina T; James AM; Colby KB; Yang Y; Gale A; Jhatakia A; Kearney AY; Graziano RF; Bezman NA; Robbins MD; Cohen AD; Campbell KS
Cancer Immunol Res; 2019 Oct; 7(10):1633-1646. PubMed ID: 31431433
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
Campbell KS; Cohen AD; Pazina T
Front Immunol; 2018; 9():2551. PubMed ID: 30455698
[TBL] [Abstract][Full Text] [Related]
4. Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells.
Panaampon J; Kariya R; Okada S
Cancer Immunol Immunother; 2022 Oct; 71(10):2497-2509. PubMed ID: 35262781
[TBL] [Abstract][Full Text] [Related]
5. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.
Balasa B; Yun R; Belmar NA; Fox M; Chao DT; Robbins MD; Starling GC; Rice AG
Cancer Immunol Immunother; 2015 Jan; 64(1):61-73. PubMed ID: 25287778
[TBL] [Abstract][Full Text] [Related]
6. Elotuzumab Enhances CD16-Independent NK Cell-Mediated Cytotoxicity against Myeloma Cells by Upregulating Several NK Cell-Enhancing Genes.
Wang YH; Hagiwara S; Kazama H; Iizuka Y; Tanaka N; Tanaka J
J Immunol Res; 2024; 2024():1429879. PubMed ID: 38444839
[TBL] [Abstract][Full Text] [Related]
7. Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.
Taniwaki M; Yoshida M; Matsumoto Y; Shimura K; Kuroda J; Kaneko H
Mediterr J Hematol Infect Dis; 2018; 10(1):e2018014. PubMed ID: 29531651
[TBL] [Abstract][Full Text] [Related]
8. Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab.
Einsele H; Schreder M
Ther Adv Hematol; 2016 Oct; 7(5):288-301. PubMed ID: 27695618
[TBL] [Abstract][Full Text] [Related]
9. CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.
Malaer JD; Mathew PA
Am J Cancer Res; 2017; 7(8):1637-1641. PubMed ID: 28861320
[TBL] [Abstract][Full Text] [Related]
10. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.
Collins SM; Bakan CE; Swartzel GD; Hofmeister CC; Efebera YA; Kwon H; Starling GC; Ciarlariello D; Bhaskar S; Briercheck EL; Hughes T; Yu J; Rice A; Benson DM
Cancer Immunol Immunother; 2013 Dec; 62(12):1841-9. PubMed ID: 24162108
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
van Rhee F; Szmania SM; Dillon M; van Abbema AM; Li X; Stone MK; Garg TK; Shi J; Moreno-Bost AM; Yun R; Balasa B; Ganguly B; Chao D; Rice AG; Zhan F; Shaughnessy JD; Barlogie B; Yaccoby S; Afar DE
Mol Cancer Ther; 2009 Sep; 8(9):2616-24. PubMed ID: 19723891
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of serum soluble SLAMF7 in multiple myeloma.
Ishibashi M; Soeda S; Sasaki M; Handa H; Imai Y; Tanaka N; Tanosaki S; Ito S; Odajima T; Sugimori H; Asayama T; Sunakawa M; Kaito Y; Kinoshita R; Kuribayashi Y; Onodera A; Moriya K; Tanaka J; Tsukune Y; Komatsu N; Inokuchi K; Tamura H
Oncotarget; 2018 Oct; 9(78):34784-34793. PubMed ID: 30410677
[TBL] [Abstract][Full Text] [Related]
13. The Clinical Pharmacology of Elotuzumab.
Passey C; Sheng J; Mora J; Tendolkar A; Robbins M; Dodge R; Roy A; Bello A; Gupta M
Clin Pharmacokinet; 2018 Mar; 57(3):297-313. PubMed ID: 28779463
[TBL] [Abstract][Full Text] [Related]
14. Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients' selection and perspective.
Trudel S; Moreau P; Touzeau C
Onco Targets Ther; 2019; 12():5813-5822. PubMed ID: 31410026
[TBL] [Abstract][Full Text] [Related]
15. Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab.
Chen WC; Kanate AS; Craig M; Petros WP; Hazlehurst LA
Cancer Manag Res; 2017; 9():307-314. PubMed ID: 28744161
[TBL] [Abstract][Full Text] [Related]
16. Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns.
Danhof S; Rasche L; Mottok A; Steinmüller T; Zhou X; Schreder M; Kilian T; Strifler S; Rosenwald A; Hudecek M; Einsele H; Gerhard-Hartmann E
Ann Hematol; 2021 Jun; 100(6):1537-1546. PubMed ID: 33575947
[TBL] [Abstract][Full Text] [Related]
17. PD-1 blockade enhances elotuzumab efficacy in mouse tumor models.
Bezman NA; Jhatakia A; Kearney AY; Brender T; Maurer M; Henning K; Jenkins MR; Rogers AJ; Neeson PJ; Korman AJ; Robbins MD; Graziano RF
Blood Adv; 2017 May; 1(12):753-765. PubMed ID: 29296719
[TBL] [Abstract][Full Text] [Related]
18. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
Palumbo A; Sonneveld P
Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
[TBL] [Abstract][Full Text] [Related]
19. Restoration of NK Cell Cytotoxic Function With Elotuzumab and Daratumumab Promotes Elimination of Circulating Plasma Cells in Patients With SLE.
Humbel M; Bellanger F; Fluder N; Horisberger A; Suffiotti M; Fenwick C; Ribi C; Comte D
Front Immunol; 2021; 12():645478. PubMed ID: 33828555
[TBL] [Abstract][Full Text] [Related]
20. Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells.
Guo H; Cruz-Munoz ME; Wu N; Robbins M; Veillette A
Mol Cell Biol; 2015 Jan; 35(1):41-51. PubMed ID: 25312647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
